Levosalbutamol offers health care provider and patients a safe, well tolerated and efficacious bronchodilator. Levosalbutamol appears to be more efficacious than RAC in terms of PEFR, SPO2 and asthma score while deleterious effects of tachycardia and fall in Serum K+ levels were seen with RAC and the total cost of therapy remained comparable. Hence Levosalbutamol should be considered as first line therapy in situations in which a short acting beta agonist is warranted.

Nebulized salbutamol (2.5 mg) diluted in 2.5 ml NS was administered 3 times during the 1st in Group A and Levosalbutamol (6.3 mg) diluted in 2.5 ml NS to Group B. The total drug volume was 2.5 ml in nebulizing chamber & nebulized over a period of 8-10 minutes and patient was instructed to inhale from his mouth.

A significant hypokalaemia occurred but extra caution needs to be taken when subjecting patients with gastroenteritis, on oral steroids, diuretics, underlying renal or hepatic disease, cardiac cases etc. who are more prone for to develop the electrolyte imbalances to nebulized salbutamol.